Back to results
US 10,950,326 B2Granted
Method for personalized selection of a drug for a subject
AssigneeCipherome, Inc.
InventorsJu Han Kim, Su Yeon Baik, Soo Youn Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method and a system for selecting a drug customized on the basis of individual protein information by using individual genome sequences. The method and the system of the present invention can predict the individual side effects or danger of a certain drug by analyzing the sequence of the exon region of a gene encoding various proteins involved in the pharmacokinetics or pharmacodynamics of a predetermined drug or drug group, and have high reliability and are widely applicable and universal.
Claims13
A method for personalizing selection of a drug for a subject using individual genome sequence variations of the subject, comprising:
- obtaining, by a computer system, information regarding gene sequences of the subject for a set of genes involved in pharmacodynamics or pharmacokinetics of a drug group, wherein the drug group consists of a plurality of drugs with a same ATC code, wherein the same ATC code is selected from ATC codes for ACE inhibitors, analgesics, anti-diabetes, antidepressants, antihistamines for systemic use, antihypertensives, anxiolytics and hypnotics/sedatives, beta blocking agents, calcium channel blockers, diuretics, drugs for obstructive airway diseases, lipid modifying agents, proton pump inhibitors, sex hormones and modulators of the genital system, and thyroid therapy;
- determining, by the computer system, gene sequence variation information indicating variations present in the gene sequences involved in the pharmacodynamics or pharmacokinetics of the group;
- for each gene of the set of genes:
- determining, by the computer system, a gene sequence variation score, the gene sequence variation score being a numerical score indicating degree of variations in the gene that cause an amino acid sequence variation in a protein encoded by the gene or cause a transcription control variation, thereby causing change or damage to a structure or function of the protein;
- storing, by the computer system, the determined gene sequence variation scores for the genes;
- for each protein encoded by a gene of the set of genes:
- calculating, by the computer system, an individual protein damage score for the protein by using [Equation 2], wherein [Equation 2] is:
- S
- g
-
- (
- v
- 1
- ,
- …
-
- ,
-
- v
- n
- )
- =
- (
- ∏
- i
- =
- 1
- n
-
- v
- i
- w
- i
- )
- 1
- /
- ∑
- i
- =
- 1
- n
-
- w
- i
- wherein Sg is the individual protein damage score of a protein encoded by a gene g, n is the number of target sequence variations for analysis among sequence variations of the gene g, vi is a gene sequence variation score of an ith gene sequence variation, and wi is a weighting assigned to the gene sequence variation score vi of the ith gene sequence variation;
- storing, by the computer system, the individual protein damage scores for the proteins, each individual protein damage score representing a summary of the gene sequence variation scores for the gene encoding the corresponding protein;
- for each drug in the drug group:
- calculating, by the computer system, an individual drug score by using [Equation 4], wherein [Equation 4] is:
- S
- d
-
- (
- g
- 1
- ,
- …
-
- ,
-
- g
- n
- )
- =
- (
- ∏
- i
- =
- 1
- n
-
- g
- i
- w
- i
- )
- 1
- /
- ∑
- i
- =
- 1
- n
-
- w
- i
- wherein Sd is the individual drug score of a drug d, n is a number of proteins encoded by one or more genes involved in the pharmacodynamicsor pharmacokinetics of the drug group d, gi is a protein damage score of a protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d, and wi is a weighting assigned to the protein damage score gi of the protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d;
- storing, by the computer system, the individual drug scores for the drugs in the drug group;
- ranking, by the computer system, drugs in the drug group by comparing the individual drug scores for the drugs;
- selecting a drug for treatment based on the ranking;
- and
- treating the subject with the selected drug.
88 more elements
A computer-readable storage medium comprising stored instructions, wherein the instructions when executed by a processor cause the processor to perform steps comprising:
- obtaining information regarding gene sequences of a subject for a set of genes involved in pharmacodynamics or pharmacokinetics of a drug group, wherein the drug group consists of a plurality of drugs with a same ATC code, wherein the same ATC code is selected from ATC codes for ACE inhibitors, analgesics, anti-diabetes, antidepressants, antihistamines for systemic use, antihypertensives, anxiolytics and hypnotics/sedatives, beta blocking agents, calcium channel blockers, diuretics, drugs for obstructive airway diseases, lipid modifying agents, proton pump inhibitors, sex hormones and modulators of the genital system, and thyroid therapy;
- determining gene sequence variation information indicating variations present in the gene sequences involved in the pharmacodynamics or pharmacokinetics of the drug group;
- for each gene of the set of genes:
- determining, by the computer system, a gene sequence variation score, the gene sequence variation score being a numerical score indicating degree of variations in the gene that cause an amino acid sequence variation in a protein encoded by the gene or cause a transcription control variation, thereby causing change or damage to a structure or function of the protein;
- storing the determined gene sequence variations scores for the genes;
- for each protein encoded by a gene of the set of genes
- calculating an individual protein damage score for the protein by using [Equation 2], wherein [Equation 2] is:
- S
- g
-
- (
- v
- 1
- ,
- …
-
- ,
-
- v
- n
- )
- =
- (
- ∏
- i
- =
- 1
- n
-
- v
- i
- w
- i
- )
- 1
- /
- ∑
- i
- =
- 1
- n
-
- w
- i
- wherein Sg is the individual protein damage score of a protein encoded by a gene g, n is the number of target sequence variations for analysis among sequence variations of the gene g, vi is a gene sequence variation score of an ith gene sequence variation, and wi is a weighting assigned to the gene sequence variation score vi of the ith gene sequence variation;
- storing the individual protein damage scores for the proteins, each individual protein damage score representing a summary of the gene sequence variation scores for the gene encoding the corresponding protein;
- for each drug in the drug group:
- calculating an individual drug score by using [Equation 4], wherein [Equation 4] is:
- S
- d
-
- (
- g
- 1
- ,
- …
-
- ,
-
- g
- n
- )
- =
- (
- ∏
- i
- =
- 1
- n
-
- v
- i
- w
- i
- )
- 1
- /
- ∑
- i
- =
- 1
- n
-
- w
- i
- wherein Sd is the individual drug score of a drug d, n is a number of proteins encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d, gi is a protein damage score of a protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d, and wi is a weighting assigned to the protein damage score gi of the protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d;
- storing the individual drug scores for the drugs in the drug group;
- ranking drugs in the drug group by comparing the individual drug scores for the drugs;
- selecting a drug for treatment based on the ranking;
- and
- treating the subject with the selected drug.
88 more elements
Dependencies are inferred from the claim text.